ASH 2021 Lymphoma In-depth

Parsaclisib Elicits ‘Rapid and Durable’ Responses in Relapsed/Refractory Follicular Lymphoma

The median duration of response was 14.7 months.

Tipifarnib Yields Responses in Relapsed/Refractory PTCL

The overall response rate was 56% in patients with angioimmunoblastic T-cell lymphoma.

Rates of ICANS, Steroid Use Higher With Axicabtagene Ciloleucel Than With Tisagenlecleucel

Axicabtagene ciloleucel was associated with higher rates of grade 3-5 ICANS and corticosteroid use.

Pembrolizumab Plus ICE: ‘Acceptable’ Salvage for Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”

Romidepsin Plus CHOEP Falls Short in Newly Diagnosed Peripheral T-Cell Lymphoma

Adding romidepsin to CHOEP did not improve progression-free survival in transplant-eligible, newly diagnosed peripheral T-cell lymphoma.

Umbralisib Plus Ublituximab Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma

Researchers sought to determine whether umbralisib plus ublituximab would be safe and active in patients with relapsed/refractory marginal zone lymphoma.